INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR
RESEARCH & DEVELOPMENT
SJIF 2019: 5.222 2020: 5.552 2021: 5.637 2022:5.479 2023:6.563 2024: 7,805
eISSN :2394-6334 https://www.ijmrd.in/index.php/imjrd Volume 12, issue 02 (2025)
501
ISCHEMIC MYOCARDIUM: PATHOPHYSIOLOGY, DIAGNOSIS AND MANAGEMENT
Murtazayeva Xadicha Nuriddinovna
Teacher of Termez branch Tashkent medical academy
Choriyev Firdavs Farxodovich
Student of Termez branch of Tashkent Medical Academy
Abstract:
Ischemic myocardium results from insufficient coronary blood flow, leading to
myocardial hypoxia and metabolic disturbances. The primary cause is atherosclerotic coronary
artery disease (CAD), which contributes to chronic coronary syndromes (CCS) and acute coronary
syndromes (ACS), including unstable angina, NSTEMI, and STEMI. This review explores the
pathophysiological mechanisms, clinical presentation, diagnostic modalities, and management
strategies for ischemic myocardium. It also discusses emerging therapies, including PCSK9
inhibitors, anti-inflammatory treatments, and regenerative medicine approaches. A multidisciplinary
approach integrating medical therapy, lifestyle interventions, and revascularization techniques
remains essential in reducing cardiovascular morbidity and mortality.
Introduction:
Cardiovascular disease remains the leading cause of death worldwide, with ischemic
myocardium playing a central role in the pathogenesis of ischemic heart disease (IHD). The primary
mechanism involves an imbalance between myocardial oxygen supply and demand due to coronary
artery obstruction, endothelial dysfunction, and microvascular disease. Understanding the
underlying pathophysiology, early detection, and evidence-based management strategies is essential
to improving patient outcomes.
Pathophysiology of Ischemic Myocardium
Ischemic myocardium results from reduced perfusion, leading to metabolic derangements and
myocardial injury. Key pathophysiological events include:
Atherosclerosis and Coronary Obstruction
Endothelial Dysfunction:
Early-stage atherosclerosis is characterized by reduced nitric oxide (NO)
production and increased expression of pro-inflammatory cytokines, adhesion molecules (ICAM-1,
VCAM-1), and oxidized LDL.
Plaque Formation and Progression:
Macrophage infiltration and smooth muscle cell proliferation
lead to fibrous cap formation, increasing the risk of rupture.
Plaque Rupture and Thrombosis: Exposure of thrombogenic plaque components triggers platelet
aggregation and thrombus formation, precipitating ACS.
Ischemic Cascade and Cellular Injury
Early Ischemia: Reduced oxygen supply shifts myocardial metabolism to anaerobic glycolysis,
leading to ATP depletion, lactic acid accumulation, and intracellular acidosis.
Myocyte Dysfunction:
Impaired Na+/K+ ATPase activity results in intracellular sodium and
calcium overload, disrupting myocardial contractility and increasing the risk of arrhythmias.
INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR
RESEARCH & DEVELOPMENT
SJIF 2019: 5.222 2020: 5.552 2021: 5.637 2022:5.479 2023:6.563 2024: 7,805
eISSN :2394-6334 https://www.ijmrd.in/index.php/imjrd Volume 12, issue 02 (2025)
502
Irreversible Myocardial Necrosis:
Prolonged ischemia (>20-30 minutes) leads to cardiomyocyte
death, inflammation, and fibrosis, contributing to heart failure (HF).
Microvascular Dysfunction:
Patients with ischemia with non-obstructive coronary arteries
(INOCA) exhibit microvascular dysfunction due to endothelial and smooth muscle abnormalities,
impairing vasodilation and coronary flow reserve.
Clinical Presentation of Chronic Coronary Syndrome (CCS)
• Stable angina pectoris (predictable exertional chest pain, relieved by rest/nitroglycerin).
• Symptoms correlate with coronary stenosis (>70% luminal narrowing).
• May present as silent ischemia in diabetic and elderly patients.
Diagnostic Approach
Electrocardiography (ECG)
(ECG) remains the
first-line diagnostic tool
for detecting myocardial
ischemia and infarction. It provides critical information about ischemic severity, location, and
progression. Changes in ECG patterns correlate with the
degree of myocardial ischemia and
infarction
, guiding treatment decisions.
Pathophysiology of ECG Changes in Ischemia
Myocardial ischemia alters
transmembrane ion gradients
, particularly potassium (K+) and
calcium (Ca2+), affecting
depolarization and repolarization
.
• ST-segment depression (NSTEMI/unstable angina) vs. elevation (STEMI).
• T-wave
inversions in ischemic territories.
Biomarkers of Myocardial Injury. Serum troponins and CK-MB (creatine kinase-MB)are readily
detectable and reliable cardiac-specific biomarkers of subclinical myocardial injury. This study
explores the roles of cTnI (cardiac troponin I) and CK-MB in hypertrophic cardiomyopathy (HCM)
• Cardiac Troponins (I/T): High specificity for myocardial necrosis.
•
Creatine Kinase-MB (CK-MB): Useful for detecting reinfarction.
Invasive Coronary Angiography.
Cardiac catheterisation is an invasive diagnostic procedure that
provides important information about the structure and function of the heart. It usually involves
taking X-rays of the heart's arteries (coronary arteries) using a technique called coronary
angiography or arteriography.
• Gold standard for high-risk patients to evaluate coronary stenosis.
Among patients who are candidates for treatment with thrombolytic agents, careful management of
blood pressure is critical before and during the administration of alteplase (recombinant tissue
plasminogen activator [rtPA]), and for the ensuing 24 hours. Excessively high blood pressures are
associated with intracerebral hemorrhage after thrombolytic administration.
INTERNATIONAL MULTIDISCIPLINARY JOURNAL FOR
RESEARCH & DEVELOPMENT
SJIF 2019: 5.222 2020: 5.552 2021: 5.637 2022:5.479 2023:6.563 2024: 7,805
eISSN :2394-6334 https://www.ijmrd.in/index.php/imjrd Volume 12, issue 02 (2025)
503
Thrombolytic therapy is not given to patients who have a systolic blood pressure above 185 mmHg
or a diastolic blood pressure above 110 mmHg despite non-aggressive blood pressure-lowering
attempts. While there is no established definition of “non-aggressive” blood pressure reduction, a
common approach is to use a maximum of two to three attempts with parenteral medications, with
options including labetalol, enalaprilat or nicardipine. Uncontrolled blood pressure is an uncommon
reason for ineligibility of IV alteplase for AIS.
Conclusion:
Ischemic myocardium remains a leading contributor to cardiovascular morbidity and
mortality. Early diagnosis, evidence-based pharmacotherapy, and timely revascularization are
crucial in improving survival. Future research should focus on novel lipid-lowering strategies, anti-
inflammatory interventions, and regenerative therapies to enhance myocardial recovery and long-
term outcomes.
References
1. Fuster V, Badimon L, et al. “Pathogenesis of atherosclerosis: The role of thrombosis.” J Am Coll
Cardiol, 2023.
2. Ibanez B, et al. “2023 ESC Guidelines for the management of acute coronary syndromes.” Eur
Heart J, 2023.
3. O’Donoghue ML, et al. “The efficacy of PCSK9 inhibitors in reducing cardiovascular events.” N
Engl J Med, 2022.
4. Ridker PM, et al. “Anti-inflammatory therapy for atherosclerosis: Insights from the CANTOS
trial.” Lancet, 2021.
5. Yellon DM, Hausenloy DJ. “Myocardial reperfusion injury: Mechanisms and therapies.” Nat Rev
Cardiol, 2023.
